Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) shares shot up 9.1% during trading on Thursday . The company traded as high as $16.60 and last traded at $16.92. 65,250 shares were traded during trading, a decline of 66% from the average session volume of 191,177 shares. The stock had previously closed at $15.50.
Analyst Ratings Changes
A number of research firms have commented on RAPP. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 target price on shares of Rapport Therapeutics in a report on Tuesday, July 8th. Citizens Jmp began coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They set a "mkt outperform" rating for the company.
Check Out Our Latest Research Report on RAPP
Rapport Therapeutics Price Performance
The business's 50-day moving average price is $12.37 and its two-hundred day moving average price is $11.85. The company has a market capitalization of $611.01 million and a P/E ratio of -4.85.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.09. Research analysts expect that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.
Insider Buying and Selling at Rapport Therapeutics
In other news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $14.00, for a total transaction of $119,000.00. Following the transaction, the insider directly owned 435,142 shares of the company's stock, valued at $6,091,988. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Hedge Funds Weigh In On Rapport Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its stake in Rapport Therapeutics by 38.9% in the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock worth $86,000 after purchasing an additional 1,352 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Rapport Therapeutics in the 4th quarter worth $34,000. Deutsche Bank AG acquired a new position in Rapport Therapeutics in the 4th quarter worth $41,000. JPMorgan Chase & Co. boosted its stake in Rapport Therapeutics by 77.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,170 shares of the company's stock worth $127,000 after purchasing an additional 3,137 shares during the period. Finally, Corebridge Financial Inc. boosted its stake in Rapport Therapeutics by 79.1% in the 1st quarter. Corebridge Financial Inc. now owns 8,271 shares of the company's stock worth $83,000 after purchasing an additional 3,653 shares during the period.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access